Details for New Drug Application (NDA): 212123
✉ Email this page to a colleague
The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.
Summary for 212123
Tradename: | TAUVID |
Applicant: | Avid Radiopharms Inc |
Ingredient: | flortaucipir f-18 |
Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 212123
Generic Entry Date for 212123*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 212123
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123 | NDA | Eli Lilly and Company | 0002-1220 | 0002-1220-48 | 1 VIAL, MULTI-DOSE in 1 CAN (0002-1220-48) / 100 mL in 1 VIAL, MULTI-DOSE |
TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123 | NDA | Eli Lilly and Company | 0002-1220 | 0002-1220-50 | 1 VIAL, MULTI-DOSE in 1 CAN (0002-1220-50) / 50 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 30ML (8.1-51mCi/ML) | ||||
Approval Date: | May 28, 2020 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 28, 2025 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | May 26, 2032 | Product Flag? | Substance Flag? | Y | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 50ML (8.1-51mCi/ML) | ||||
Approval Date: | May 28, 2020 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 28, 2025 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY |
Complete Access Available with Subscription